基本信息
views: 480
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer.
The primary goal of our multidisciplinary group of investigators is to find more effective treatments for patients with brain tumors. Our program is especially interested in the development of novel targeted molecular therapies. We currently have a large number of clinical trials of these agents in progress. Recently we also started trials of combinations of targeted molecular agents, which are likely to be more effective than treatment with single agents alone. As part of these trials, we are also genotyping the tumors and correlating them with response to treatment in the hope of identifying subgroups of patients who are particularly likely to benefit. In addition, we are conducting clinical trials evaluating novel inhibitors of angiogenesis, chemotherapy combinations, intratumoral agents delivered by convection, and tumor vaccines. A second focus of our program is the development of novel therapies for meningiomas, brain metastases, and leptomeningeal metastases; clinical studies evaluating targeted molecular agents and novel chemotherapeutic agents against these cancers are under way. We also collaborate with colleagues in Pediatric Neuro-Oncology and the Department of Cancer Biology in a preclinical program directed at identifying novel targets for therapy and evaluating new agents for clinical trials.In addition, our program has a strong interest in quality-of-life issues affecting patients with brain tumors, in particular, venous thromboembolic disease. We are currently studying the molecular basis of venous thromboembolism and evaluating the benefit of prophylactic anticoagulation. Furthermore, we are about to begin studies evaluating the role of prophylactic anticonvulsants in patients with malignant glioma who have not had seizures and medications such as methylphenidate for radiation-induced fatigue.
The primary goal of our multidisciplinary group of investigators is to find more effective treatments for patients with brain tumors. Our program is especially interested in the development of novel targeted molecular therapies. We currently have a large number of clinical trials of these agents in progress. Recently we also started trials of combinations of targeted molecular agents, which are likely to be more effective than treatment with single agents alone. As part of these trials, we are also genotyping the tumors and correlating them with response to treatment in the hope of identifying subgroups of patients who are particularly likely to benefit. In addition, we are conducting clinical trials evaluating novel inhibitors of angiogenesis, chemotherapy combinations, intratumoral agents delivered by convection, and tumor vaccines. A second focus of our program is the development of novel therapies for meningiomas, brain metastases, and leptomeningeal metastases; clinical studies evaluating targeted molecular agents and novel chemotherapeutic agents against these cancers are under way. We also collaborate with colleagues in Pediatric Neuro-Oncology and the Department of Cancer Biology in a preclinical program directed at identifying novel targets for therapy and evaluating new agents for clinical trials.In addition, our program has a strong interest in quality-of-life issues affecting patients with brain tumors, in particular, venous thromboembolic disease. We are currently studying the molecular basis of venous thromboembolism and evaluating the benefit of prophylactic anticoagulation. Furthermore, we are about to begin studies evaluating the role of prophylactic anticonvulsants in patients with malignant glioma who have not had seizures and medications such as methylphenidate for radiation-induced fatigue.
Research Interests
Papers共 1254 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Neuro-oncologyno. 7 (2024): 1181-1194
Edward K. Avila,Steven Tobochnik, Sara K. Inati,Johan A. F. Koekkoek, Guy M. Mckhann,James J. Riviello, Roberta Ruda,David Schiff, William O. Tatum,Jessica W. Templer, Michael Weller,Patrick Y. Wen
Y. -T. Cheng, C. -H. Chien,K. -M. Hsieh,Y. -H. Huang,P. Y. Wen,W. -J. Lin,Y. Lu, F. Aziz, C. -P. Lee,K. -T. Lin,C. -Y. Chen,J. C. Chen,
PHYSICAL REVIEW Ano. 2 (2024)
Neuro-oncologyno. Supplement_2 (2024): S165-S172
Neuro-oncologyno. 5 (2024): 965-974
Journal of clinical oncology : official journal of the American Society of Clinical Oncologyno. 13 (2024): 1542-1552
NEURO-ONCOLOGYno. 1 (2024): 2-4
Neurosurgeryno. Supplement_1 (2024): 34-35
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn